• Global demand for electric vehicles expected to grow at annual rate of 15.6 percent over next five years, presenting huge opportunities for lithium producers
• Demand for lithium, key ingredient in lithium-ion batteries powering EVs, projected to more than double by 2022
• Promising results from original exploration holes on Ollague Property are basis of additional, deeper drilling efforts
• Lithium Chile owns 15 projects in heart of world’s highest-grade lithium district
• Global lithium-ion battery market expected to reach $93.1 billion by 2025, growing at a CAGR of 17 percent

Lithium Chile Inc. (TSX.V: LITH) (OTCQB: LTMCF), the largest private owner of lithium-rich land in Chile, is deep into an aggressive multi-project drill program that, to date, has provided encouraging results from sampling tests. The company’s efforts at its wholly owned Ollague project, located in the Antofagasta Region of Chile, are being rewarded, according to a recent news release (http://ibn.fm/kWA9d).

Of the first four exploration holes that are now completed, results indicated grades in the brine ranging up to 480 mg/l of lithium, with the grades steadily increasing from 120 meters to the final depth of 300 meters. Based on this preliminary information, Lithium Chile is pursuing a fifth hole in the center of the basin, just north of the third and fourth holes, and has scheduled a deeper target depth of 500 meters.

“Drilling a fifth hole at Ollague not only reflects the encouraging data we have collected on our first four holes but also reflects our belief that Ollague has the potential to be an exciting new lithium discovery,” Lithium Chile’s president and CEO Steve Cochrane said in the release.

Global demand for lithium is expected to more than double from 26,700 tonnes in 2018 to 58,300 tonnes in 2022, according to data and analytics company GlobalData, as reported in an article published by Proactive Investors Australia (http://ibn.fm/XxUcM). Most of that demand is tied to the future of electric vehicles as nations begin to wean their citizens off of vehicles powered by the combustion engine and on to EVs energized by lithium-ion batteries and similar rechargeable battery components.

According to McKinsey’s Electric Vehicle Index, global sales of new electric vehicles passed one million units in 2017, with EV producers expecting a surge in the appetite for their products (http://ibn.fm/O1Ejz). An article in Forbes (http://ibn.fm/KihsC) points out that China leads market share in this space by purchasing 48 percent of the EVs sold today, followed by European customers at 26 percent.

Lithium Chile’s own analysis of the market agrees that EVs are driving lithium growth, which underpins the reason for the company’s accelerated exploration program. Grand View Research projects that the global lithium-ion battery market will reach $93.1 billion by 2025, growing at a compound annual growth rate of 17 percent (http://ibn.fm/LGEKZ). Increased usage of lithium-ion batteries in electric vehicles, portable consumer electronics and grid storage systems owing to its high energy density and high safety level is expected to drive market demand.

Increased consumption of lithium and support investment in mine expansions across Chile and Australia, as well as new mine development such as that underway in Lithium Chile’s Ollague project area, could eventually help meet the demands of green technology as global leaders continue efforts to reduce greenhouse gas emissions and affect climate change.

For more information, visit the company’s website at http://ibn.fm/LTMCF

• Functional beverage market estimated at $14 billion worldwide currently; CBD hemp extract market expected to hit $22 billion by 2022
• Phivida Holdings’ recent announcement of new Oki brand heralds introduction of full spectrum hemp extract-infused iced teas, flavored waters
• Company also has joint venture with WeedMD Inc. to produce cannabis-infused beverages under Cannabis Beverages, Inc. label

The concept that beverages may serve a “functional” purpose has developed within the health and wellness industry as cannabis producers examine ever-expanding options for putting the plant’s properties to use. Hemp-cultivated cannabinoid innovator Phivida Holdings Inc. (CSE: VIDA) (OTCQX: PHVAF) is pursuing the beneficial possibilities of new drink products infused with active hemp extract while marketing its existing line of Vida+ brand hemp oil extracts and capsules.

With less than a month remaining until Canada approves a full range of medical and recreational drug uses of the cannabis plant nationwide, cannabis industry companies and their ancillaries are preparing for an onslaught of consumers interested in mining cannabis’ therapeutic potential.

Phivida’s core purpose of using whole plant nutrition and natural ingredients as the best way to maintain overall physical health and balance has led to the creation of its premium, full spectrum cannabinoid line of extract and capsule products designed to help people feel their best. The company’s recent announcement of a joint venture with licensed Canadian medical marijuana producer WeedMD Inc. (TSX.V: WMD) (OTC: WDDMF) (FSE: 4WE) to create a line of cannabis-infused drinks under the Cannabis Beverages, Inc. (“CanBev”) label will take Phivida’s product line to a new retail audience with its expected rollout in 2019 (http://ibn.fm/CdoDo). Phivida also recently announced a distribution plan for its new Oki brand iced tea and flavored water products through an exclusive agreement with Natural Specialty Sales to utilize that company’s network of up to 2,400 retail outlets across the United States (http://ibn.fm/yJVdU).

Natural Specialty Sales’ network includes Whole Foods, Sprouts Farmers Market and national co-op grocers. The Oki beverages will be sold in recyclable 16-ounce glass bottles and contain 10 mg of hemp extract. The initial production run included 100,000 bottles, with 150,000 more scheduled for distribution exclusively in the United States. Supplements are also available in tinctures or capsules ranging in dosage from 600 to 1,800 mg of active hemp extract.

The CanBev products will be distributed throughout Canada and online, with legalized international market outlets expected to follow. WeedMD will supply the cannabinoid extracts for the drinks while Phivida will lead new product innovation, research and development, formulation, packaging and branding, and will sublicense its current and future trademarks, intellectual property, branding and packaging to CanBev.

“The size of the functional beverage market is estimated to be approximately $14 billion and the hemp extract market is poised to explode to $22 billion by 2022,” Chief Marketing Officer Mike Cornwell said in a news release. “We’re proud to be able to offer consumers a new line of products that could benefit them, using formats like beverages and supplements, which are relatively unchartered by other companies in our category. We truly are in the midst of very exciting times.”

While the idea of drinkable cannabis was once considered unthinkable among marijuana’s recreational smokers, recent studies have shown that beer consumption has decreased significantly in the United States where cannabis has been legalized (http://ibn.fm/YWiBc), prompting industry efforts to combine the two products and retain the consumer base, or even increase it.

Cannabis’ reputation has transformed from that of a silly, intoxicating “weed” to a respected and in-demand medicinal herb for treating select nervous system disorders. Cannabis-infused beverages and other consumables are now poised to also gain a recreational use following among people who want to enjoy its relaxing properties but are offended by stinky and unhealthful smoke, as well as the hangover that alcohol can leave with drinkers who otherwise enjoy its recreational use.

For more information, visit the company’s website at www.Phivida.com

• Four-hole drill project in famed Lithium Triangle nearing completion
• First assay of Lithium Chile’s underway drill project shows results on par with average grades in neighboring Argentina exploration
• Lithium Chile may alter drill plan to probe to greater depths and add fifth hole to project as a result of first hole analysis

Test results have identified important lithium-bearing brines in the first hole drilled as part of a four-hole lithium-seeking project in Chile’s Salar de Ollague, fueling excitement about the project and expectations that the other three holes could further identify the zone as a potentially significant mineralization discovery for Lithium Chile Inc. (TSX.V: LITH) (OTCQB: LTMCF).

Lithium Chile announced on August 23 that the drill project is validating the results of a transient electromagnetic survey (“TEM”) completed in March that revealed the zone’s potential as a source for the lightweight metal regarded as so critical for modern computerized devices worldwide — especially for powering electric vehicles now that a major upturn in that industry is expected during the coming decade (http://ibn.fm/uahOP).

Initial drill site testing of the core and liquid samples retrieved from Hole DDH-OLL-01-18 showed that the project had struck a continuous 180-meter salinity zone beginning at a depth of 110 meters. The August 23 news release states that the assay of the drill hole at internationally accredited laboratory ALS Patagonia’s nearby facilities returned results of up to 480 mg/L of lithium, with an average grade over the last 60 meters of 470 mg/L lithium.

In the news release, Lithium Chile President and CEO Steve Cochrane noted that the assays “rival the average grades in Argentina” and that he is “delighted” the first results of the company’s drilling activity are already showing promise. The company also believes that the results may have been diluted by drilling fluids and fresher water uphole from the salinity zone, leaving open the possibility of higher grades with actual production at the site.

Assay results are expressed in measurements of milligrams per liter (mg/L) or parts per million (ppm) equivalents showing the amount of lithium found at brine-friendly salars (dry lake beds). Economically productive lithium finds may result from brines with concentrations beginning at a few hundred mg/L. Albermarle’s huge lithium brine mine in the United States is founded over finds between 190 and 200 mg/L (http://ibn.fm/7FUTi). A test well less than a mile from DDH-OLL-01-18 returned fluid results assayed at 1,220 mg/L of lithium.

Lithium has become an in-demand metal because of the critical heat-reducing function it plays in the modern lithium-ion batteries that power everything from smartphones to environmentally friendly automobiles. Demand for lithium is expected to triple during the coming decade, with most of the new growth occurring in the electronics industry, according to minerals research agency Roskill (http://ibn.fm/jgdTJ).

Chile is a significant area for mineral exploration in the famed “Lithium Triangle” that also encompasses Argentina and Bolivia. The second hole in Lithium Chile’s four-hole project was drilled in what the TEM identified as the shallower southwestern edge of the Ollague salar, near DDH-OLL-01-18. The third and fourth holes are nearer the center of the salar, where the company expects to find the mineralization continuous to deeper regions.

Core and liquid samples from the second site are being assayed, the drilling for the third hole has been completed and the fourth drill hole is in progress. Because the first hole showed increasing grades of lithium as the drill reached lower depths, Lithium Chile is evaluating the feasibility of going deeper than planned with the fourth hole and even adding a new, deeper drill hole to the project, according to the news release.

The company’s portfolio includes sections of 14 salars and one laguna (surface water) complex in Chile, covering some 377,824 acres (152,900 hectares). Once the current four-hole exploration is completed, it plans to start similar projects at four other advanced-stage sites, potentially wrapping up before the end of Q3.

For more information, visit the company’s website at http://ibn.fm/LTMCF

• CytoDyn signs definitive agreement to acquire privately held ProstaGene
• Gets access to CCR5 technologies related to cancer
• Lead candidate PRO 140 set for Investigational New Drug (IND) application in first cancer indication, expanding CytoDyn’s focus beyond HIV

With its planned acquisition of ProstaGene, LLC, CytoDyn Inc. (OTCQB: CYDY) is expanding its focus beyond HIV and graft-versus-host disease to open up a new front in the fight against cancer. ProstaGene is developing metastasis control technology that targets the chemokine receptor type 5 (CCR5), a protein on the surface of white blood cells. Metastasis is the spread of cancer beyond the original tumor, a phenomenon that contributes to the disease’s deadliness. Studies have suggested that the use of CCR5 antagonists as adjuvants may bolster anti-tumor immune responses.

CytoDyn recently announced signing a definitive agreement to acquire privately held ProstaGene, expected to be finalized in November. CytoDyn also confirmed that Richard G. Pestell, M.D., Ph.D., M.B.A., F.A.C.P., F.R.A.C.P., founder and CEO of ProstaGene, will join CytoDyn as its future chief medical officer (http://ibn.fm/QOBNu). The deal transfers or assigns certain intellectual property rights held by ProstaGene and Pestell to CytoDyn. Of particular interest to CytoDyn is the metastasis control technology and the work done in this area by ProstaGene aimed at developing a therapy that prevents metastasis in prostate, breast and other cancers. ProstaGene is also developing a companion test to identify those patients who will respond to the therapy, estimated at around 50 percent of prostate and breast cancer cases, resulting in the potential for an extensive market. Both the metastasis technology and IP are based on blocking the CCR5 receptor from antigens.

CCR5 is also thought to act as a portal for many forms of the human immunodeficiency virus (HIV) that causes acquired immunodeficiency syndrome, or AIDS, which is why it has been of interest as a drug target to CytoDyn. The normal function of CCR5 is to bind chemokines, molecules that regulate inflammation. However, the receptor can also provide a gateway to HIV; the GP120 protein of HIV first attaches to the CD4 receptor on the cell membrane and then is able to bind to the co-receptor CCR5. Fusing of the membranes of the virus and the immune cell then occurs and genetic material from HIV enters the cell, infecting the cell.

CytoDyn’s lead product candidate, PRO 140 (leronlimab), targets CCR5. PRO 140 is a viral-entry inhibitor, a new class of HIV/AIDS therapies that works by blocking the entry of the virus to healthy cells. PRO 140 works by attaching to the same portion of the CCR5 co-receptor to which HIV normally binds. The PRO 140 antibody physically blocks HIV from attaching to the CCR5 co-receptor and arrests the completion of the second step in the entry process. The HIV is, consequently, rendered ineffective.

CytoDyn has completed a Phase 3 study of PRO 140 in combination with current highly active anti-retroviral therapy (HAART) regimens, and it plans to file a Biological License Application for that usage. The company is also conducting a Phase 3 study of PRO 140 as a potential single-agent treatment for HIV.

The company recently received approval to increase the dosage in its Phase 3 monotherapy trials of PRO 140. Due for completion by year-end (http://ibn.fm/pMGdn), “patients who finish the study will move into a FDA-cleared rollover study.”

The approach taken by PRO 140 has a distinct advantage over other therapies. Other HIV drugs that target CCR5 interact with the pocket of the receptor and thereby inhibit binding of not only the HIV, but chemokines, which may have a number of adverse consequences because of the disruption of the chemokine inflammatory response. However, PRO140 blocks entry of the HIV and yet permits normal chemokine binding, leading to potentially fewer side effects.

CytoDyn is now preparing to move PRO 140 into clinical trials in cancer. In August, CytoDyn announced that PRO140 had been shown effective at inhibiting the growth of a human colon carcinoma cell line (SW480) in a prominent mouse model. The results were statistically significant and provide the basis for filing an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for a clinical trial in colon carcinoma patients (http://ibn.fm/tIEYt).

For more information, visit the company’s website at www.CytoDyn.com

• The new HUB880 Explorer ultra-high pressure based system will be used by research laboratories worldwide in food-borne pathogen research to potentially maximize food safety
• Pressure BioSciences has sold a second system to Tennessee State University’s Public Health Microbiology Laboratory
• The development of laboratory-scale high pressure research instruments is one of the major product areas upon which the company is focusing, the other being its novel Ultra Shear Technology (UST) platform
• UST, the centerpiece of the company’s recently announced, USDA-funded ($891,000) development program with The Ohio State University, is a scalable food processing method with the potential to make healthy, nutritious, great tasting beverages and liquid foods with extended shelf-lives without requiring chemical additives
• Feedback from early users of the HUB880 Explorer are expected to help guide the development of the company’s first UST commercial instrument

Pressure BioSciences Inc. (OTCQB: PBIO) announced recently the sale of the first two instruments from its newest line of high-pressure instrument systems. The HUB880 Explorer is a high-pressure based system that will enable public health, microbiology, food science, agriculture and other research scientists to study the manner in which pressure can kill food pathogens.

The first customer of the new system is a leading Japanese research institute that’s conducting trials in the fields of food and agricultural development. The aim is to maximize safety while also reducing production costs. The Japanese researchers will rely on the HUB880 Explorer to study the effects of high pressure on food manufacturing and the destruction of food-borne pathogens during the process, according to a company press release (http://ibn.fm/FNSWY).

Pressure BioSciences Vice President of Marketing and Sales Dr. Nate Lawrence revealed that the second customer is the Public Health Microbiology Laboratory at Tennessee State University. The laboratory will use the newly-released pressure instrument to acquire a better understanding of enteric pathogens, such as E. coli, salmonella and listeria.

Every year, foodborne pathogens like the ones mentioned above contribute to 420,000 deaths worldwide. They also cause the cumulative loss of 33 million years of healthy living on an annual basis, according to the Public Health Microbiology Laboratory.

The Public Health Microbiology Laboratory has been relying on Pressure BioSciences’ pressure-based instruments for years, which has enabled the publication of multiple scientific articles on food quality, as well as safety and handling of foodborne pathogens. According to Dr. Lawrence, these publications have been well-received in the scientific community.

Through the use of the new HUB880 Explorer, researchers will become capable of reaching higher pressure levels and working with larger sample sizes. This way, the manner in which pathogens contribute to spoilage and safety hazards will be studied more thoroughly. Because of this enhancement, the HUB880 Explorer could potentially lead to higher revenue levels in the foreseeable future, Dr. Lawrence noted.

Pressure BioSciences President and CEO Richard T. Schumacher said that the company is concentrating its efforts in two fields – pressure-based research instruments for use in scientific research settings and the Ultra Shear Technology, which is a scalable food processing method. The aim of UST is to address the limitations of using standard high-pressure processing and other food processing technologies in the quest to develop a scalable, enabling food processing method that can result in safer, great tasting, longer shelf-life, clean label (no chemical additives) food.

The Ultra Shear Technology combines high-pressure with intense shear forces while simultaneously limiting the exposure to high temperature. Recently, an $891,000 grant was awarded to Ohio State University for the development of the technological platform in collaboration with Pressure BioSciences. A significant portion of the funds will be allocated to the design, development and manufacturing of two prototype instruments (a bench-top and a floor model). According to Schumacher, the company believes that once the prototype instruments have been made, UST processing will result in the ability to process beverages and liquid foods that will have excellent taste and extended shelf life, but will not require chemical additives.

For more information, visit the company’s website at www.PressureBioSciences.com

• Search engine features focused on cannabis commerce
• “Business media” platform that makes networking easier
• One-stop shop for both consumers and commercial operators

There’s a good chance that, very soon, someone who wants information on cannabis commerce will “NUG-L” with an application developed by NUGL Inc. (OTC: NUGL), in much the same way that they “Google” a topic. The tech company, located in Chino Hills, California, is aiming to become a leader in fostering communication and business relations in the cannabis space. To do so, it has developed a distinct platform that is part Google, part LinkedIn, which will allows users to not only find information on products, services and much more related to cannabis, but also facilitate networking and alliances between brands and service providers. NUGL’s leading edge, first-of-its-kind search app and online directory for the marijuana industry may soon be a one-stop shop for dispensaries, hydro stores, vape shops, brands and strains, as well as doctors, lawyers and other service professionals.

As Technical Engineer CJ Melone of NUGL explained in a recent interview (http://ibn.fm/zkWYZ), “We basically built an application that addresses every type of business in the 420 sector… and the businesses range from services, such as a CPA, a real estate agent… we cover all the storefronts, such as dispensaries and hydro stores, and we really are focusing on brands. And a brand could range from a vape pen coming out or a certain strain of marijuana, and what we’re seeing is that as the industry is becoming more sophisticated and it’s evolving, people and users are looking for that level of sophistication. They don’t want to just find marijuana or a store that sells it, they want to find a certain strain or brand of marijuana, and it’s just a natural step in evolution.”

“So we built profiles that address all these types of companies and it’s good, because it gives brands and services the ability to network ‘on the back end’, and a brand could start setting up distribution, and start making connections with dispensaries; a type of nutrient could start making connections with hydro stores or grow houses; and services can start making connections to people that need it. And what’s even more important is that this is a ‘value-add’ to the user, since they can find more things online and in a more detailed way, so it’s a win-win on both sides,” he continued.

The “profiles” are a feature that is proving to be especially favored. The wealth of information a profile provides “almost alleviates the need for a company to have a web site.” They will undoubtedly play an important role as dispensaries and other cannabis retail establishments search for suppliers and service providers. Indeed, this B2B capability of the application gives NUGL a unique position in the cannabis sector, making the company not simply a search platform but a “business media” portal. NUGL expects that as businesses and professionals become more familiar with the platform, this B2B characteristic will take on increasing importance. It is presently engaging in a variety of educational outreaches to teach the community how to use the back end of the software.

The company continues to enhance the application – it is rolling out new features every week – based on feedback received from the ecosystem of cannabis businesses, service providers and consumers, and it expects to start charging for some services in the very near future.

“We are going to start monetizing soon,” explained Melone. “You know software is a funny thing. Sometimes it’s better to start charging 5 million eyeballs later, than 500 hundred eyeballs today… We are getting into the market very methodically. We are gaining users and brands. We are putting together some strategic alliances. It’s going good. We are growing every day. We are not trying to do things on a whim. We are in this for the long haul.”

For more information, visit the company’s website at http://ibn.fm/NUGL

• A syndicate of underwriters is to purchase 3.8 million units at C$5.27 per unit
• Sale terms are an amendment of previously announced agreement to sell 1.9 million units
• Sunniva is closer to achieving full vertical integration in California with launch of Sunniva-branded product lines commencing in Q4 2018

Sunniva Inc. (CSE: SNN) (OTCQX: SNNVF), a vertically-integrated medical cannabis provider, aims to raise C$20 million through the sale of units of the company to a syndicate of underwriters spearheaded by Beacon Securities Limited and Canaccord Genuity Corp., according to a company press release (http://ibn.fm/HVqPi).

Sunniva announced that the syndicate will purchase 3.8 million units priced at C$5.27 per unit, an amendment of the previously publicized agreement which said that the syndicate was to buy 1.9 million units. Subject to the approval of the Canadian Securities Exchange, the closing date of the deal will be October 10. The funds realized from the sale will go toward working capital, among other corporate expenses.

Sunniva recently released its second quarter results, at which time the company’s management said that they looked forward to future revenue opportunities (http://ibn.fm/EQesV). In a news release, CEO Dr. Anthony Holler said, “We made great progress in Q2 2018 towards our goal of becoming a truly vertically integrated cannabis company in the U.S. In California, construction progressed at our phase one 325,000 square foot state-of-the-art Sunniva California Campus with completion targeted by the end of this year and first harvest expected in Q1 2019. Our extraction facility began generating revenue this quarter. We continue to secure new contracts and are excited about the future revenue opportunities in this and other vertical channels that maximize the synergies with our Vapor Connoisseur device business.”

In the six months up to June 2018, Sunniva’s total revenue amounted to C$9.6 million, against a net loss of C$11.2 million, compared to a C$11.7 million loss in the same period last year.

Speaking of the company’s immediate future plans, Dr. Holler said that its focus in California and the U.S. is to leverage its cultivation and extraction facilities and aggressively expand upstream distribution and retail opportunities to achieve full vertical integration from seed to sale, “which will include a focus on soon launching Sunniva branded product lines in various product categories including flower, extracted products, vaporizers and beverages.”

The first half of the year saw Sunniva entering separate agreements to provide distilled oil products to two leading California brands. Sunniva’s subsidiary, CP Logistics, has a deal with Farmacy Phactory, a producer of high-terpene strains of cannabis. CP Logistics will also produce distilled oil products for Cali Gold.

Sunniva has experienced significant expansion over the last year, including beginning construction of a new 759,000 square foot facility in Okanagan Falls, Canada, and opening a new clinic in its Natural Health Services referral network of cannabis-related clinics.

Dr. Holler continued, “In Canada, we received our Confirmation of Readiness letter for a license from Health Canada and broke ground and commenced construction on the 759,000 square foot Sunniva Canada Campus in Okanagan Falls, British Columbia. Our Natural Health Services’ clinics reported another strong quarter of revenue generation and together with the future production from the Sunniva Canada Campus, provide a solid foundation for future Canadian growth opportunities.”

For more information, visit the company’s website at www.sunniva.com

• CytoDyn will present on October 1 at 9 a.m. EST (6 a.m. PST) at The Microcap Conference at the Essex House in New York City, with live webcast available
• CYDY is a biotechnology company developing humanized monoclonal antibodies for the treatment of multiple therapeutic indications, such as HIV, tumor metastasis and graft-vs-host disease

CytoDyn Inc. (OTCQB: CYDY) management is set to present at The Microcap Conference on October 1 at the Essex House in New York at 9 a.m. EST (http://ibn.fm/CEGgV). The MicroCap presentation will be available on live webcast, and a replay will be hosted on the investor’s section of the company’s website at http://ir.CytoDyn.com.

CYDY is in advanced clinical development with PRO 140, a leading monoclonal antibody for the treatment and prevention of HIV, which offers potential both in combination with other HIV treatments and as single-agent therapy. PRO 140 is a humanized IgG4 monoclonal antibody that blocks CCR5, a cellular receptor that plays multiple roles with implications in HIV infection, tumor metastasis and immune signaling.

In the setting of HIV/AIDS, PRO 140 belongs to a new class of therapeutics called viral-entry inhibitors; it masks CCR5, thus protecting healthy T cells from viral infection by blocking the predominant HIV (R5) subtype from entering those cells. At the same time, PRO 140 does not appear to interfere with the normal function of CCR5 in mediating immune responses. PRO 140 has been the subject of seven clinical trials, each demonstrating efficacy by significantly reducing or controlling HIV viral load in human test subjects. PRO 140 has been designated a “fast track” product by the FDA. The PRO 140 antibody appears to be a powerful antiviral agent leading to potentially fewer side effects and less frequent dosing requirements compared with daily drug therapies currently in use.

In the setting of cancer, research has shown that CCR5 plays a central role in tumor invasion and metastasis and that expression of CCR5 is an indicator of disease status in several cancers. Moreover, researchers have shown that drugs that block CCR5 can block tumor metastases in laboratory and animal models of aggressive breast and prostate cancer. In human pilot trials, CCR5 inhibition has been shown to remarkably limit colon cancer metastasis. CytoDyn is conducting additional research with PRO 140 in the cancer setting and plans to initiate Phase 2 human clinical trials when appropriate.

The CCR5 receptor also plays a central role in modulating immune cell trafficking to sites of inflammation, and it is crucial for the development of acute graft-versus-host disease (GvHD) and other inflammatory conditions. Clinical studies by others have shown that blocking CCR5 using a chemical inhibitor can reduce the clinical impact of acute GvHD without significantly affecting the engraftment of transplanted bone marrow stem cells. CytoDyn is currently conducting a Phase 2 clinical study with PRO 140 to further support the concept that the CCR5 receptor on engrafted cells is critical for the development of acute GvHD and that blocking this receptor from recognizing certain immune signaling molecules is a viable approach to mitigating acute GvHD. The FDA has granted orphan drug designation to PRO 140 for the prevention of graft-versus-host disease (GvHD).

For more information, visit the company’s website at www.CytoDyn.com

• Bitcoin wallet application SingleCoin is now available for iOS and Android
• SingleCoin expansion plans include supporting multiple currencies and cryptos
• Original “Shark Tank” member Kevin Harrington signed as company spokesman for SingleCoin with national ad campaign featuring virtual wallet’s secure method of storing cryptocurrencies
• Recent launch of LastMile Delivery platform gives small to mid-size companies, including those in the cannabis industry, the ability to streamline, track deliveries

SinglePoint, Inc. (OTCQB: SING) is simplifying the oftentimes confusing financial nuances of owning, storing, sending and receiving bitcoin through its SingleCoin virtual wallet, now available for iOS and Android via the Apple App Store and Google Play. SinglePoint President Wil Ralston announced the launch of SingleCoin during an appearance on MoneyTV with Donald Baillargeon (http://ibn.fm/NiwKT).

“SingleCoin is live, it’s launched on Android and iOS. We’ve launched at SinglePoint.com; you can now actually can see the preview and the links there to directly download the application,” Ralston stated in the interview. Original “Shark Tank” member Kevin Harrington recently completed filming a commercial promoting the SingleCoin app that is now being scheduled for broadcast on several national media outlets.

SingleCoin requires no signup, quickly sends updated, market-priced bitcoin to any wallet address, makes it easy to share a wallet address across different social networks and receive bitcoin and simplifies transaction history by tracking each transaction in a compact, specially designed list. SingleCoin stores private keys in a secure keychain placed only on the device and not in an online backup. To view Ralston’s full interview on MoneyTV, visit: http://ibn.fm/he9I7.

As a diversified holding company with operations in multiple industries and verticals, including two high-performing market sectors in legal cannabis and cryptocurrencies, SinglePoint continues to add to its diverse portfolio, which provides multiple revenue streams. The recent unveiling of LastMile Delivery is a perfect example of SinglePoint’s ability to identify a need and fill it with an exceptional product.

The LastMile Delivery platform aims to provide SMBs the ability to streamline their deliveries and give customers the insight and predictability of when a delivery will arrive, a company news release states (http://ibn.fm/gOtym). Available to businesses throughout the world, LastMile Delivery leverages advanced routing and location technology, providing location tracking, estimated time of arrival, product tracing and inventory, omnichannel e-commerce experience, and scheduled arrival time. The agnostic platform works for any genre of business from cannabis delivery services to pizza shops. Merchants can set up from order inception to delivery completion or just use the dispatch and track capabilities.

“Almost a year ago we started to build out LastMile… and we finished it and we’re so excited,” SinglePoint CEO Greg Lambrecht stated in a recent MoneyTV interview (http://ibn.fm/k25gM). “We really built it for the dispensaries, so when someone ordered cannabis they can see exactly when that delivery was coming. Having said that, this is for any business that can’t afford to do their own.”

SinglePoint reported significant year-over-year improvements of nearly 100 percent in second quarter revenues, as compared to the same quarter of 2017. The company also uplisted as a fully reporting company to the OTCQB Venture Marketplace, creating additional opportunities for growth (http://ibn.fm/gOR75).

For more information, visit the company’s website at www.SinglePoint.com

• SeeThruEquity provides research insight into underfollowed smallcap and microcap equities
• CIIX recently announced FY2018 results, with 40.5 percent YoY growth
• Growth potential for CIIX in cryptocurrency offerings

The leading independent equity research firm SeeThruEquity recently announced an update note on ChineseInvestors.com, Inc. (OTCQB: CIIX). Headquartered in Midtown Manhattan in New York City, SeeThruEquity maintains one of the industry’s most extensive databases of opt-in institutional and high net worth investors. The research firm’s core mission is to provide impactful, high quality research on underfollowed smallcap and microcap equities.

CIIX is a relatively undiscovered specialized financial information company dedicated to Chinese-speaking investors worldwide. The company focuses on delivering market analysis and education in the Chinese language. In addition, CIIX capitalizes on the market potential of cannabis-infused health and wellness products and cryptocurrency investments. With the upcoming CBD spinoff set to take place by year-end, the company plans to focus back on its original mission of providing financial information and services to the larger Chinese community in the U.S. and elsewhere.

CIIX reported revenue growth of 40.5 percent over FY2017 for FY2018. The growth is credited to the company’s focus on consumer products and services in the hemp oil, CBD and cryptocurrency markets, as well as an increase in revenue for investor relations and subscription-based investor news products. The company anticipates significant growth in its hemp, CBD and cryptocurrency initiatives in FY2019, with moderate growth overall.

SeeThruEquity noted that CIIX was seeking to raise $3 million in private placement in August 2018. The research firm anticipates that CIIX will continue to seek external capital to cover costs until growth initiatives are able to support free cash flow generation.

CIIX has expanded its offerings to target the fast-growing cryptocurrency market through education and trading subscription services for Chinese-speaking investors. NewCoins168.com and the Daily Cryptocurrency Chinese Video Newscast from the NYSE cover the emerging digital currency market. In 2018, the company also launched Bitcoin Millionaire VIP Livestream and Bitcoin Trading Academy. Currently, there are plans to install a cryptocurrency ATM network and domestic online coin-to-coin exchange.

For more information, visit the company’s website at www.ChineseInvestors.com